HLA-B27 Antigen Test

Most people with chronic back pain will never know whether their immune system is wired to attack their own spine. HLA-B27 (human leukocyte antigen B27) is a genetic marker that, when present, dramatically increases the odds of developing a group of inflammatory conditions called spondyloarthritis. These conditions can quietly erode spinal joints for years before they show up on an X-ray, and the average delay between first symptoms and diagnosis is six to eight years. Knowing your HLA-B27 status can compress that timeline.

Unlike most blood tests, HLA-B27 is not a number that fluctuates. It is a yes-or-no answer determined by your DNA. You either carry the gene or you do not, and the result never changes. A single test tells you for life. That makes this one of the simplest tests to interpret, but understanding what a positive result actually means, and what it does not mean, requires context.

What HLA-B27 Actually Is

Every cell in your body displays a set of surface proteins that act like an identity badge for the immune system. These proteins, part of a system called the human leukocyte antigen (HLA) complex, hold fragments of proteins from inside the cell and present them to immune cells for inspection. If the fragments look normal, the immune system moves on. If they look foreign, as they would during a viral infection, the immune system attacks.

HLA-B27 is one specific version of these identity-badge proteins. About 6 to 8% of people of European descent carry it, with prevalence varying widely by ethnicity. What makes HLA-B27 unusual is that it tends to misfold inside cells, triggering stress responses that promote inflammation. It can also form abnormal pairs on the cell surface that activate parts of the immune system involved in inflammatory disease. These quirks help explain why carrying this gene raises the risk of certain autoimmune conditions so dramatically.

Ankylosing Spondylitis and Axial Spondyloarthritis

The strongest disease link for HLA-B27 is with ankylosing spondylitis, a condition where chronic inflammation gradually fuses the vertebrae of the spine. Between 90 and 95% of people with ankylosing spondylitis carry HLA-B27, and the association carries an odds ratio above 50, making it one of the strongest gene-disease links in all of medicine. A large meta-analysis pooling 35 studies with nearly 9,000 patients and over 19,000 healthy controls found that HLA-B27 carriers had roughly 16 times the risk of developing ankylosing spondylitis compared to non-carriers.

The broader category, called axial spondyloarthritis, includes both the classic form visible on X-rays and an earlier stage (non-radiographic axial spondyloarthritis) where inflammation is present but has not yet caused visible bone damage. HLA-B27 is found in 70 to 90% of patients across both forms. If you have inflammatory back pain that started before age 45, morning stiffness lasting more than 30 minutes, and improvement with movement rather than rest, a positive HLA-B27 test significantly raises the probability that spondyloarthritis is the cause.

Eye Inflammation

Acute anterior uveitis, a painful inflammation of the front of the eye that causes redness, light sensitivity, and blurred vision, is tightly linked to HLA-B27. Roughly 44% of people who develop anterior uveitis test positive for HLA-B27. In a prospective study of patients presenting with acute anterior uveitis, about two-thirds were found to have spondyloarthritis, and roughly 70% of those had never been diagnosed. An episode of uveitis can be the first visible sign that an inflammatory joint disease is already underway.

Inflammatory Bowel Disease and Reactive Arthritis

HLA-B27 also links to arthritis that develops after gut or genitourinary infections (reactive arthritis) and to joint disease in people with Crohn's disease or ulcerative colitis. Among patients with inflammatory bowel disease who also develop spondylitis, roughly 50 to 75% carry HLA-B27, compared to much lower rates in those with IBD alone. In reactive arthritis, about half of tested patients carry HLA-B27.

Mortality Risk

A large prospective study of over 32,600 American veterans followed for an average of 4.6 years found that HLA-B27 positive individuals had a 15% higher risk of death from any cause compared to HLA-B27 negative individuals, after adjusting for age, sex, race, and related diagnoses. Among those who also had spondyloarthritis, the mortality risk was 35% higher. Among those without a spondyloarthritis diagnosis, the association did not reach statistical significance.

What a Positive Result Means (and Does Not Mean)

A positive HLA-B27 result does not mean you have or will develop spondyloarthritis. Only 2 to 10% of people who carry HLA-B27 ever develop one of these conditions. The risk climbs to 20 to 30% if you also have a first-degree relative (parent, sibling, child) with spondyloarthritis. Most HLA-B27 positive individuals remain healthy throughout their lives.

A negative result does not rule out spondyloarthritis either. Between 10 and 30% of patients with axial spondyloarthritis are HLA-B27 negative. The test has a sensitivity of about 50% and a specificity of about 90% for axial spondyloarthritis, with a positive likelihood ratio of 5.0. That means a positive result meaningfully raises the odds that symptoms are caused by spondyloarthritis, but it cannot confirm or exclude the diagnosis on its own. Diagnosis requires combining clinical symptoms, imaging, and lab findings.

Prevalence by Ethnicity

HLA-B27 prevalence varies widely across populations, which affects how the test performs in different groups.

In populations where HLA-B27 is less common, such as among American Blacks, the relative risk associated with a positive result is lower, and a negative result is less useful for ruling out disease. The diagnostic value of this test depends heavily on your ethnic background and the prevalence of spondyloarthritis in your population.

Subtypes That Matter

Not all versions of HLA-B27 carry the same risk. More than 160 subtypes have been identified, and they differ by just a few amino acids. The subtypes most strongly linked to ankylosing spondylitis are B27:05 (the most common worldwide), B27:02 (more common in Mediterranean populations), B27:04 (East Asian populations), and B27:07 (South Asian and Middle Eastern populations). Two subtypes, B27:06 and B27:09, are not associated with disease despite being classified as HLA-B27. Standard testing may report you as HLA-B27 positive even if you carry a non-disease-associated subtype. If your clinical picture is unclear, molecular-level subtyping can resolve this ambiguity.

Testing Methods and Accuracy

Labs use several methods to detect HLA-B27, and the method matters. Flow cytometry, the most common approach (used by about 52% of laboratories), works by tagging HLA-B27 proteins on the surface of white blood cells with fluorescent antibodies. It is fast and inexpensive, but it has the highest error rate at 5.33%. A major source of error is cross-reactivity with a closely related protein called HLA-B7, which can cause false positive results.

Molecular methods, such as PCR (polymerase chain reaction, a technique that amplifies and detects specific DNA sequences) and sequence-specific oligonucleotide testing, look directly at your DNA rather than the protein on cell surfaces. These methods are more accurate, with error rates as low as 0%. They can also distinguish between disease-associated and non-disease-associated subtypes. If a flow cytometry result is equivocal, confirming with a molecular method is the recommended next step.

When Results Can Be Misleading

Because HLA-B27 is genetically determined, the usual confounders that affect blood tests, such as fasting, time of day, exercise, illness, or medications, do not apply. Your result will be the same whether you test at 6 a.m. or midnight, fasting or fed, healthy or sick. No medication can change whether you carry the gene.

The only source of misleading results is technical. When flow cytometry uses a single antibody to detect HLA-B27, false positives and equivocal results are common. One study found that using a single antibody clone produced false positives in over half of tested samples. Using two antibody clones together, along with pre-selecting the right cell population, dramatically improved accuracy. If your result is borderline or unexpected, ask your lab which method was used and whether molecular confirmation is available.

One Test, Lifetime Answer

HLA-B27 is unique among biomarkers because it does not change. There is no biological variation from day to day, no need to track a trend, and no reason to retest unless there is a specific concern about lab error. One accurate test gives you a permanent answer.

That said, knowing your status early has value precisely because the diseases it predicts can develop slowly over years. If you are HLA-B27 positive and you later develop inflammatory back pain, uveitis, or joint swelling after an infection, you and your doctor already have an essential piece of the diagnostic puzzle in hand. That can shave years off the diagnostic delay that is so common with spondyloarthritis. Think of HLA-B27 testing not as a one-time snapshot, but as a piece of your permanent health profile that can be referenced any time a relevant symptom arises.